Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of gentiopicroside in treatment of non-alcoholic fatty liver diseases

A technology for fatty liver disease and gentiopicroside, applied in the field of application of gentiopicroside in the treatment of non-alcoholic fatty liver disease, can solve the controversial and uncertain effects of NAFLD treatment

Inactive Publication Date: 2018-04-20
NORTHWEST UNIV
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the therapeutic effect of some of the above-mentioned drugs on NAFLD is controversial or uncertain. Seeking safe and effective therapeutic drugs and methods must be a hot issue that the medical circles in various countries continue to pay attention to.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gentiopicroside in treatment of non-alcoholic fatty liver diseases
  • Application of gentiopicroside in treatment of non-alcoholic fatty liver diseases
  • Application of gentiopicroside in treatment of non-alcoholic fatty liver diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0075] Medicinal gentiopicroside is prepared into tablets. Taking the production of 1000 tablet products as an example, the raw materials and auxiliary materials used and their weight ratios are as follows:

[0076] Gentiopicroside 200 g

[0077] Starch 100 g

[0078] Its preparation process is carried out according to the conventional process of pharmacy tablets, each tablet weighs 0.3 g, and each tablet contains gentiopicroside 200 mg.

[0079] Usage and Dosage: Take orally, 1 tablet each time, once a day, reduce as appropriate for children, a course of treatment is 15 days.

Embodiment 2

[0081] Medicinal gentiopicroside is prepared into capsules, taking the production of 1000 capsule products as an example, the raw materials and auxiliary materials used and their weight ratios are as follows:

[0082] Gentiopicroside 200 g

[0083] Starch 100 g

[0084] Its preparation process is carried out according to the conventional process of pharmaceutical capsules, each capsule weighs 0.3 g, and each capsule contains 200 mg of gentiopicroside.

[0085] Usage and dosage: Oral, 1 capsule each time, once a day, reduce it for children, a course of treatment is 15 days.

Embodiment 3

[0087] Medicinal gentiopicroside is prepared into granules. Taking the production of 1000 granule products as an example, the raw materials and auxiliary materials used and their weight ratios are as follows:

[0088] Gentiopicroside 200 g

[0089] Sucrose 400g

[0090] Dextrin 400 g

[0091] Its preparation process is carried out according to the conventional process of pharmaceutical granules, each bag weighs 1 g, and 1 g contains gentiopicroside 200 mg.

[0092] Usage and dosage: Oral, 1 bag each time, once a day, reduce it for children, a course of treatment is 15 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of gentiopicroside in preparation of medicines for treating non-alcoholic fatty liver diseases. Experiments prove that the gentiopicroside can achieve the following effects in non-alcoholic fatty liver diseases caused by fructose: obviously limiting increase of mouse weight and decrease of food ration, lowering triglycerides (TG), uric acid (UA) and glucose (GLU) as well as levels of serum glutamic oxalacetic transaminase (AST) and glutamic-pyruvic transaminase (ALT), obviously alleviating vacuolar degeneration of hepatic cells and deposition of fatty acidscaused by fructose, lowering levels of tumor necrosis factors (TNF-alpha) and interleukin 6 (IL-6) in hepatic tissues, raising levels of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px)in the hepatic tissues and lowering levels of malondialdehyde (MDA) and superoxide anions (O2<->). Results show that the gentiopicroside can achieve the effects of obviously promoting metabolism of the liver on fat, obviously improving and increasing the antioxidant stress level of the liver and alleviating hepatocellular injury, so that the aim of treating the fatty liver diseases is achieved.

Description

technical field [0001] The invention relates to the application of gentiopicroside in the preparation of medicines for treating nonalcoholic fatty liver disease. technical background [0002] Nonalcoholic fatty liver disease (NAFLD) refers to a clinicopathological syndrome characterized by excessive fat deposition in liver cells caused by factors other than alcohol and other definite factors. According to the degree of pathological changes and whether the diseased liver tissue is accompanied by inflammation and fibrosis, nonalcoholic fatty liver disease can be divided into: simple fatty liver, nonalcoholic steatohepatitis, and nonalcoholic steatohepatitis-related cirrhosis. At the same time as the onset of nonalcoholic fatty liver disease, it may be accompanied by complications such as metabolic syndrome, diabetes, and hyperuricemia. Among the many causes, obesity caused by overnutrition has become one of the main pathogenic factors today. Insulin resistance, leptin resist...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P1/16
CPCA61K31/7048
Inventor 杨洋孙文基李静张勇民
Owner NORTHWEST UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com